Related Experiment Videos

Growth preservation after brief growth hormone therapy in chronic renal insufficiency

B L Warshaw1, M Shaw, R N Fine

  • 1Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Pediatric Nephrology (Berlin, Germany)
|February 1, 1997
PubMed

Insights

Recombinant human growth hormone (rhGH) treatment effectively improved height in a child with chronic renal insufficiency. Growth gains were sustained long-term even after rhGH therapy cessation.

Area of Science:

  • Pediatric Endocrinology
  • Nephrology
  • Growth Hormone Therapy

Background:

  • Short stature is a common complication in children with chronic renal insufficiency (CRI).
  • Growth hormone deficiency can be a contributing factor to impaired growth in pediatric CRI.
  • Recombinant human growth hormone (rhGH) is a potential therapeutic option for growth failure in children with CRI.

Observation:

  • A pediatric patient with short stature secondary to CRI was treated with rhGH.
  • The treatment duration with rhGH was 20 months.
  • Growth velocity and height standard deviation score (SDS) were monitored.

Findings:

  • Catch-up growth was achieved during the 20-month rhGH treatment period.
  • The positive effect on height SDS was sustained for 4 years after discontinuing rhGH therapy.
  • No further rhGH administration was required to maintain the achieved growth improvement.

Implications:

  • rhGH therapy can be an effective intervention for improving linear growth in children with CRI.
  • Sustained growth benefits may persist after treatment cessation, suggesting a potential long-term impact.
  • This case highlights the potential for rhGH to normalize growth trajectories in pediatric patients with renal insufficiency.

Related Concept Videos